Overview

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Treatments:
Apatinib